DiaSorin S.p.A.

Milan Stock Exchange:DIA.MI

Sector

🏥 Health Care

Industries

🧬 Biotechnology

🔬 Clinical Trials

🩺 Medical Instruments

💻 Telehealth

Location

Italy

Market Cap

USD 5.86 B

Share Price

USD 108.81

Avg Daily Volume

152,641

Change (1 day)

0.09%

Change (1 year)

7.61%

Change (YTD)

5.03%

DiaSorin S.p.A. Enterprise Value to EBITDA (EV/EBITDA) on June 23, 2025: 15.87

DiaSorin S.p.A. Enterprise Value to EBITDA (EV/EBITDA) is 15.87 on June 23, 2025, a -10.79% change year over year. EV/EBITDA ratio compares the enterprise value to the EBITDA; lower suggests more favorable company valuation.

DiaSorin S.p.A. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 20.38 on June 23, 2025, which is 28.47% above the current Enterprise Value to EBITDA (EV/EBITDA).
DiaSorin S.p.A. 52-week low Enterprise Value to EBITDA (EV/EBITDA) is 14.45 on June 23, 2025, which is -8.96% below the current Enterprise Value to EBITDA (EV/EBITDA).
DiaSorin S.p.A. average Enterprise Value to EBITDA (EV/EBITDA) for the last 52 weeks is 17.91.

Daily

From:

To:

Zoom:

Key data

Date	Enterprise Value to EBITDA (EV/EBITDA)	Free Cash Flow Yield	Dividend Yield	Market Capitalization

Milan Stock Exchange: DIA.MI

DiaSorin S.p.A.

CEO	Mr. Carlo Rosa
IPO Date	July 19, 2007
Location	Italy
Headquarters	Via Crescentino snc
Employees	3,249
Sector	🏥 Health Care
Industries Biotechnology 🔬 Clinical Trials 🩺 Medical Instruments 💻 Telehealth

Description

DiaSorin S.p.A. develops, manufactures, and distributes immunodiagnostics and molecular diagnostics testing kits in Europe, Africa, North America, Central and South America, the Asia Pacific, and China. The company provides various immunodiagnostic LIAISON platforms, including LIAISON XS, LIAISON XL, and LIAISON XL LAS; and molecular diagnostics platform comprising of LIAISON MDX for use in the amplification of nucleic acids to diagnose viral infections through the identification of virus in patient's biological sample. It has partnership agreements with QIAGEN for diagnostic solution for Latent Tuberculosis detection; TTP for the development of molecular Point-of-Care solution; and MeMed for the launch of a test differentiating between viral and bacterial infections. The company was founded in 1968 and is headquartered in Saluggia, Italy.